| Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. | |
| | |
MedLine Citation:
|
PMID: 19593744 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We studied the effects of the presence of the HLA-DR15 allele on the experimental and clinical features of myelodysplastic syndrome (MDS) by assessing the clinical data of 136 patients with MDS. We observed that the frequency of HLA-DR15 expression in MDS patients (38.7%) was significantly higher than that in the healthy controls (p < 0.01). We noted the following observations with regard to disease progression: None of the 46 HLA-DR15 positive patients with international prognostic scoring system (IPSS) scores <or=1 developed acute myeloid leukaemia (AML) during the follow-up period, while six of the 63 DR15-negative patients with the same IPSS score developed AML within a shorter follow-up period (p = 0.039). Furthermore, the incidence of poor chromosomal abnormalities, the percentage of patients with IPSS scores >or=1.5 and the presence of >or=5% blasts in the bone marrow in the DR15-positive patients were lower than the corresponding findings in the DR15-negative patients. In addition, we also recorded the following observations with regard to bone marrow (BM) failure: The bicytopenia/pancytopenia ratio in the DR15-positive patients was higher than that in the DR15-negative patients (92.4 vs. 78.3%; p = 0.029). The peripheral-neutrophil count and the platelet count in the DR15-positive patients were lower than those in the DR15-negative patients (p = 0.028 and p = 0.011, respectively). Moreover, hypocellularity was more easily detectable in the DR15-positive patients (26.4 vs. 16.9%). In addition, the BM CD4+ lymphocyte count and the CD4/CD8 ratio in the DR15-positive patients were higher than the corresponding values in the DR15-negative patients (p < 0.05 for both). However, there were no significant differences between the polarization of T-helper (T(h)) and T-cytotoxic (T(c)) cells and the cytokine levels in these two patient groups. We concluded that the presence of the HLA-DR15 allele is indicative of a genetic susceptibility to MDS and, the presence of the HLA-DR15 allele showed less association with disease progression and greater association with BM failure. |
| | |
Authors:
|
Li Xiao; Liao Qiong; Zhang Yan; Zhang Zheng; Song Luxi; Xu Li; Tao Ying; Liu Yizhi; Pu Quan |
Related Documents
:
|
20010464 - Frequency of bcr-abl gene mutations in polish patients with chronic myeloid leukemia tr... 773514 - Bacterial glutaminase in treatment of acute leukaemia. 9456644 - Analysis of oral manifestations of leukemia: a retrospective study. 20302964 - Frequency of cd4(+)cd25(hi)foxp3(+) regulatory t cells has diagnostic and prognostic va... 21254914 - 3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferat... 8553934 - High-resolution chest ct in systemic lupus erythematosus. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Hematological oncology Volume: 28 ISSN: 1099-1069 ISO Abbreviation: Hematol Oncol Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-07 Completed Date: 2010-06-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307268 Medline TA: Hematol Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 98-103 Citation Subset: IM |
Copyright Information:
|
(c) 2009 John Wiley & Sons, Ltd. |
Affiliation:
|
Department of Hematology, Sixth Hospital affiliated to Shanghai Jiaotong University, Shanghai, China. lixiao3326@yahoo.com.cn |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alleles Asian Continental Ancestry Group / genetics Bone Marrow / chemistry, pathology CD4 Lymphocyte Count CD4-CD8 Ratio Disease Progression Gene Frequency Genes, MHC Class II* Genetic Predisposition to Disease HLA-DR Antigens / genetics* Humans Interferon-gamma / analysis Myelodysplastic Syndromes / blood, genetics, immunology*, pathology Tumor Necrosis Factor-alpha / analysis |
| Chemical | |
Reg. No./Substance:
|
0/HLA-DR Antigens; 0/HLA-DR15; 0/Tumor Necrosis Factor-alpha; 82115-62-6/Interferon-gamma |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Two novel NPM1 mutations in a therapy-responder AML patient.
Next Document: Investigating the role of attachment in social comparison theories of eating disorders within a non-...